Laboratory tests considered safety parameters reflecting a glucocorticoid effect (eg, serum fasting glucose, sodium, potassium).
Patients were seen every week in the outpatient clinic for laboratory tests and safety evaluation, which was determined using the National Cancer Institute Common Toxicity Criteria (NCI-CTC, version 3.0).
Triage, face-to-face assessment in primary care, as well as evaluating clinical features, laboratory tests and safety netting, needs to be further examined [ 30].
Safety assessments included adverse events, clinical laboratory tests, ECOG patient safety and physical examinations and vital signs.
Assessments of overall safety and tolerability were based on AEs, safety laboratory tests, 12-lead electrocardiograms, vital sign measurements, physical examinations, and self-monitored blood glucose.
Safety assessments consisted of evaluation of adverse events, clinical safety laboratory tests, vital signs, weight and electrocardiograms.
Overall safety and tolerability were assessed by adverse event (AE) reports, safety laboratory tests, vital sign measurements, physical examinations and 12-lead electrocardiograms.
Safety and tolerability were evaluated based on adverse event (AE) reports, safety laboratory tests, vital sign measurements, physical examinations, SMBG and 12-lead electrocardiograms.
Safety and tolerability were assessed based on adverse event (AE) reports, safety laboratory tests, vital sign measurements, physical examinations and 12-lead electrocardiograms.
Safety and tolerability over the 52-week treatment period were evaluated based on adverse event (AE) reports, safety laboratory tests, vital sign measurements, physical examinations, SMBG and 12-lead electrocardiograms.
